Oxalic acid – important uremic toxin
Authors:
M. Mydlík 1,2; K. Derzsiová 1
Authors‘ workplace:
IV. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura, Košice, Slovenská republika, prednosta prof. MUDr. Ivan Tkáč, PhD.
1; Ústav experimentálnej medicíny Lekárskej fakulty UPJŠ, Košice, Slovenská republika, prednosta MVDr. Alojz Bomba, DrSc.
2
Published in:
Vnitř Lék 2010; 56(7): 695-701
Category:
80th Birthday - Jaroslava Blahoše, MD, DrSc.
Overview
Introduction:
Oxalic acid is thought to be a significant uremic toxin that participates in the pathogenesis of uremic syndrome.
Aim of the study was to summarise results which we obtained during the study of oxalic acid in biological fluids (plasma, saliva, urine and dialysate) in patients suffering from chronic kidney diseases (CKD), stage 3–5 and after renal transplantation.
Patients and methods:
In the retrospective study were investigated 28 healthy subjects, 112 CKD stage 1–4 patients, 39 haemodialysis patients and 27 CAPD patients. Besides 21 patients were investigated after renal transplantation. We used the following therapeutic methods: maximal water diuresis, diet with low (2 g/day) and high (15 g/day) sodium chloride intake, administration intravenous furosemide (20 mg) and renal replacement therapy [CAPD, haemodialysis (HD), haemofiltration (HF) and postdilution haemodiafiltration (HDF)] and renal transplantation. Oxalic acid was determined by spectrophotometric method using oxalate oxidase which is free from vitamin C interference. Vitamin C was determined by spectrophotometric method.
Results:
In CKD patients and those after renal transplantation direct relationships between plasma oxalic acid and serum creatinine were found (r = 0.904 and 0.943, respectively, P < 0.001). Despite of high plasma oxalic acid in uremic patients (23.1 ± 10 µmol/l), there was no significant difference in salivary oxalic acid between control subjects (126.5 ± 18 µmol/l) and CKD stage 3–4 patients (133.9 ± 23.7 µmol/l). The urinary excretion of oxalic acid during maximal water diuresis in healthy subjects (n = 15) (from 37.5 ± 17.4 to 110.2 ± 49.3 µmol/4 hours) and after intravenous furosemide (CKD stage 3–4, n = 15) (from 34.5 ± 5.5 to 66.7 ± 8.1 µmol/3 hours) increased significantly, but was not affected by high intake of NaCl in diet (CKD stage 3–4, n = 12). One tablet of Sorbifer® Durules® containing 100 mg Fe2+ and 60 mg vitamin C did not lead to further increase of uremic hyperoxalemia in haemodialysis patients. Four-hour HD, HF and HDF led to the significant decrease of plasma oxalic acid, but the most significant decrease was observed during HDF (63.3%).
Conclusion:
The results of this study indicate, that renal replacement therapy is not effective for permanent reduction of elevated plasma levels of oxalic acid – important uremic toxin.
Key words:
uremic toxin – oxalic acid – vitamin C – chronic kidney disease (CKD) – maximal water diuresis – sodium diuresis – salivary oxalic acid – renal replacement therapy – renal transplantation
Sources
1. Vanholder R, Argilés A, Baurmeister U et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24: 695–725.
2. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934–1943.
3. Vanholder R, Glorieux G, De Smet R et al. Low water-soluble uremic toxins. Adv Ren Replace Ther 2003; 10: 257–269.
4. Wills MR. Uremic toxins, and their effect on intermediary metabolism. Clin Chem 1985; 31: 5–13.
5. Levin RI, Kantoff PW, Jaffe EA. Uremic levels of oxalic acid suppress replication and migration of human endothelial cells. Atherosclerosis 1990; 10: 198–207.
6. Recht PA, Tepedino GJ, Siecke NW et al. Oxalic acid alters intracellular calcium in endothelial cells. Atherosclerosis 2004; 173: 321–328.
7. Costello JF, Smith M, Stolarski C et al. Extrarenal clearance of oxalate increases with progression of renal failure in the rat. J Am Soc Nephrol 1992; 3: 1098–1104.
8. France NC, Holland PT, Wallace MR. Contribution of dialysis to endogenous oxalate production in patients with chronic renal failure. Clin Chem 1994; 40: 1544–1548.
9. Massry SG, Glassock RJ. Textbook of Nephrology, 2 volume. 3rd ed. Baltimore: Williams & Wilkins 1995.
10. Worcester EM, Fellner SK, Nakagawa Y et al. Effect of renal transplantation on serum oxalate and urinary oxalate excretion. Nephron 1994; 67: 414–418.
11. Hatch M, Freel RW, Vaziri ND. Intestinal excretion of oxalate in chronic renal failure. J Am Soc Nephrol 1994; 5: 1339–1343.
12. Boer P, van Leersum L, Hené RJ et al. Plasma oxalate concentration in chronic renal disease. Am J Kidney Dis 1984; 4: 118–122.
13. Salyer WR, Keren D. Oxalosis as a complication of chronic renal failure. Kidney Int 1973; 4: 61–66.
14. Celasun B, Safali M, Yenicesu M. Secondary oxalosis of bone in a dialysis patient. Scand J Urol Nephrol 1995; 29: 211–214.
15. Nakazawa R, Hamaguchi K, Hosaka E et al. Cutaneous oxalate deposition in a hemodialysis patient. Am J Kidney Dis 1995; 25: 492–497.
16. Costello JF, Sadovnic MC, Smith M et al. Effect of vitamin B6 supplementation on plasma oxalate and oxalate removal rate in hemodialysis patients. J Am Soc Nephrol 1992; 3: 1018–1024.
17. Makoff R. Vitamin replacement therapy in renal failure patients. Miner Electrolyte Metab 1999; 25: 349–351.
18. Rathi S, Kern W, Lau K. Vitamin C‑induced hyperoxaluria causing reversible tubulointerstitial nephritis and chronic renal failure: a case report. J Med Case Report 2007; 1: 155.
19. Ogawa Y, Machida N, Jahana M et al. Major factors modulating the serum oxalic acid level in hemodialysis patients. Front Biosci 2004; 9: 2901–2908.
20. Schück O. Fractional sodium excretion in patients with chronic renal failure with respect to the therapy. Nephron 1982; 30: 95–96.
21. Schück O. Nefrologia pro praktické lékaře. 1. vyd. Praha: Scientia Medica 1993: 156–158.
22. Krämer BK, Pickert A, Hohmann C et al. In vivo clearance and elimination of nine marker substances during hemofiltration with different membranes. Int J Artif Organ 1992; 15: 408–412.
23. Hořejší J, Fassati M, Jícha J et al. Základy chemického vyšetřování v lékařství. 4. vyd. Praha: Státní zdravotnické nakladatelství 1964.
24. Rolton HA, McConnell KN, Modi KS et al. A simple, rapid assay for plasma oxalate in uraemic patients using oxalate oxidase, which is free from vitamin C interference. Clin Chim Acta 1989; 182: 247–254.
25. Mydlík M, Derzsiová K, Pribylincová V et al. Urinary excretion of oxalic acid in chronic renal failure and after kidney transplantation. Przegląd Lek 1996; 53 (Suppl 3): 65–69.
26. Mydlík M, Derzsiová K, Jenča A et al. Salivary oxalic acid and ascorbic acid in chronic renal failure. Proc Selected Papers of the XIII International Congress on Nutrition and Metabolism in Renal Disease. Merida (Mexico) February 28-March 4, 2006. In: Trevino-Becera A, Pineda-Sanches E, Trinida-Ramos P (eds). Bologna, Italy, Medimond S. r. l. 2006, 39–44.
27. Mydlík M, Derzsiová K, Žemberová E. Influence of water and sodium diuresis and furosemide on urinary excretion of vitamin B6, oxalic acid and vitamin C in chronic renal failure. Miner Electrolyte Metab 1999; 25: 352–356.
28. Mydlík M, Derzsiová K, Žemberová E et al. Vplyv furosemidu na vylučovanie kyseliny oxalovej, vitamínu C a vitamínu B6 pri chronickom zlyhaní obličiek. Vnitř Lék 1998; 44: 127–131.
29. Derzsiová K, Mydlík M, Boldizsár J et al. Perorálne použitie železa s vitamínom C u hemodialyzovaných chorých. Vnitř Lék 2001; 47: 210–214.
30. Mydlík M, Derzsiová K, Šváč J et al. Peritoneal clearance and peritoneal transfer of oxalic acid, vitamin C and vitamin B6 during continuous ambulatory peritoneal dialysis. Artif Organs 1998; 22: 784–788.
31. Mydlík M, Derzsiová K, Sulková S et al. Peritoneálny klírens a peritoneálny transfer kyseliny oxalovej a kyseliny askorbovej počas kontinuálnej ambulantnej peritoneálnej dialýzy (CAPD). Akt Nefrol 1995; 1: 25–28.
32. Mydlík M, Derzsiová K. Renal replacement therapy and secondary hyperoxalaemia in chronic renal failure. Kidney Int 2001; 59 (Suppl 78): S304–S307.
33. Costello JF, Sadovnic MJ, Cottington EM. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1991; 1: 1289–1298.
34. Marangella M, Vitale C, Petrarulo M et al. The clinical significance of assessment of serum calcium oxalate saturation in the hyperoxaluria syndromes. Nephrol Dial Transplat 1995; 10 (Suppl 8): 11–13.
35. Wahl R, Kallee E. Oxalic acid in saliva, teeth and tooth tartar. Eur J Clin Chem Clin Biochem 1994; 32: 821–825.
36. Mäkilä E. Salivary Vitamins. Int Z Vitamin Forsch 1968; 38: 260–269.
37. Mäkilä E, Kirveskari P. A study of ascorbic acid in human saliva. Arch Oral Biol 1969; 14: 1285–1292.
38. Bates JF, Hughes RE, Hurley RJ. Ascorbic acid status in man: measurements of salivary, plasma and white blood cell concentration. Arch Oral Biol 1972; 17: 1017–1020.
39. Blacow NW, Wade A (eds). Martindale. The Extra Pharmacopoiea. 26th ed. London: The Pharmaceutical Press 1972.
40. Dzúrik R, Dzúriková V. Diuretická liečba. 2. vyd. Martin: Osveta 1981.
41. Boer P, Beutler JJ, van Rijn HJ et al. Urinary oxalate excretion during intravenous infusion of diuretics in man. Nephron 1990; 54: 187–188.
42. Sahun G, Acikalin MF, Yalcin AU. Erythropoietin resistance as a result of oxalosis in bone marrow. Clin Nephrol 2005; 63: 402–404.
43. Dell’Aquila R, Feriani M, Mascalzoni E et al. Oxalate removal by differing dialysis techniques. ASAIO J 1992; 38: 797–800.
44. Mydlík M, Derzsiová K. Oxalic acid as a uremic toxin. J Ren Nutr 2008; 18: 33–39.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2010 Issue 7
Most read in this issue
- Laboratory diagnostics and endocrinology
- Parvovirus B19 infection – the cause of severe anaemia after renal transplantation
- The influence of testosterone on cardiovascular disease in men
- Chronic pancreatitis and the skeleton